Compare PGEN & FIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | FIVN |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2013 | 2014 |
| Metric | PGEN | FIVN |
|---|---|---|
| Price | $7.13 | $32.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 18 |
| Target Price | $8.33 | ★ $26.06 |
| AVG Volume (30 Days) | ★ 6.0M | 3.4M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 364.71 |
| EPS | 0.03 | ★ 0.25 |
| Revenue | $230,981,000.00 | ★ $1,149,088,000.00 |
| Revenue This Year | $1,115.92 | $11.39 |
| Revenue Next Year | $81.04 | $10.00 |
| P/E Ratio | $248.00 | ★ $129.20 |
| Revenue Growth | N/A | ★ 10.28 |
| 52 Week Low | $2.99 | $13.29 |
| 52 Week High | $7.49 | $34.58 |
| Indicator | PGEN | FIVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 61.21 |
| Support Level | $3.96 | $17.59 |
| Resistance Level | $7.32 | $34.58 |
| Average True Range (ATR) | 0.44 | 2.01 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 75.70 | 73.51 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.